Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual Meeting

GlobeNewswire May 31, 2015

Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

GlobeNewswire May 21, 2015

The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update

Marketwired May 15, 2015

Sunesis Pharmaceuticals Announces Presentation of VALOR Data at the 2015 ASCO Annual Meeting

GlobeNewswire May 14, 2015

Sunesis to Present at the 2015 UBS Global Health Care Conference

GlobeNewswire May 13, 2015

Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights

GlobeNewswire May 5, 2015

Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2015 Financial Results and Recent Highlights

GlobeNewswire April 28, 2015

Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report

Marketwired April 2, 2015

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights

GlobeNewswire March 12, 2015

Sunesis to Host Conference Call on March 12th to Discuss Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights

GlobeNewswire March 5, 2015

Sunesis Announces Amendment to Loan Agreement

GlobeNewswire March 2, 2015

Sunesis to Present at Upcoming Investor Conferences

GlobeNewswire February 24, 2015

Sunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference

GlobeNewswire February 18, 2015

The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments

Marketwired February 3, 2015

Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting

GlobeNewswire December 8, 2014

Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting

GlobeNewswire December 7, 2014

Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting

GlobeNewswire December 2, 2014

Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology

GlobeNewswire November 24, 2014

Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica

GlobeNewswire November 19, 2014

Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting

GlobeNewswire November 17, 2014